Free Trial

Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Entropy Technologies LP

Bio-Rad Laboratories logo with Medical background

Entropy Technologies LP lessened its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 44.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,200 shares of the medical research company's stock after selling 967 shares during the quarter. Entropy Technologies LP's holdings in Bio-Rad Laboratories were worth $292,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. Dimensional Fund Advisors LP raised its stake in shares of Bio-Rad Laboratories by 14.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 746,119 shares of the medical research company's stock valued at $245,106,000 after purchasing an additional 91,690 shares in the last quarter. Earnest Partners LLC raised its stake in shares of Bio-Rad Laboratories by 2.1% in the 4th quarter. Earnest Partners LLC now owns 618,049 shares of the medical research company's stock valued at $203,035,000 after purchasing an additional 12,500 shares in the last quarter. Ariel Investments LLC raised its stake in shares of Bio-Rad Laboratories by 48.0% in the 4th quarter. Ariel Investments LLC now owns 560,524 shares of the medical research company's stock valued at $184,138,000 after purchasing an additional 181,829 shares in the last quarter. Bank of America Corp DE raised its stake in Bio-Rad Laboratories by 705.9% during the fourth quarter. Bank of America Corp DE now owns 427,292 shares of the medical research company's stock worth $140,370,000 after acquiring an additional 374,269 shares during the period. Finally, First Pacific Advisors LP raised its stake in Bio-Rad Laboratories by 136.0% during the first quarter. First Pacific Advisors LP now owns 372,555 shares of the medical research company's stock worth $90,739,000 after acquiring an additional 214,705 shares during the period. Institutional investors and hedge funds own 65.24% of the company's stock.

Bio-Rad Laboratories Price Performance

Shares of NYSE:BIO opened at $287.06 on Friday. The firm's 50 day moving average is $249.96 and its two-hundred day moving average is $256.13. Bio-Rad Laboratories, Inc. has a 52 week low of $211.43 and a 52 week high of $387.99. The firm has a market capitalization of $7.77 billion, a P/E ratio of 24.47 and a beta of 0.90. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 EPS for the quarter, beating the consensus estimate of $1.93 by $0.68. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The company had revenue of $651.60 million for the quarter, compared to analyst estimates of $614.82 million. During the same quarter last year, the business earned $3.11 earnings per share. Bio-Rad Laboratories's revenue was up 2.1% compared to the same quarter last year. Analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on BIO shares. Royal Bank Of Canada increased their price objective on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an "outperform" rating in a research note on Friday, August 1st. Wells Fargo & Company increased their price objective on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an "equal weight" rating in a research note on Friday, August 1st. UBS Group dropped their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Citigroup dropped their price objective on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Finally, Wall Street Zen upgraded shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $333.50.

View Our Latest Analysis on BIO

About Bio-Rad Laboratories

(Free Report)

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

Featured Stories

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bio-Rad Laboratories Right Now?

Before you consider Bio-Rad Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.

While Bio-Rad Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Stocks With Explosive Upside
September Slowdown: 3 Stocks to Buy When the Pullback Comes
3 Overlooked Stocks Riding the AI Data Center Boom

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines